Skip to content
lifestyle.utv.ie
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Insilico Medicine
AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging
August 5, 2026
Insilico Medicine Launches the Industry’s First Drug Discovery and Development (DDD) Benchmark as a Service, to Evaluate Frontier AI and Foundation Models on Real-World Science
July 30, 2026
Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma
July 29, 2026
Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors
July 27, 2026
Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
June 22, 2026
Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics
June 17, 2026
Insilico Medicine and Human Longevity Announce Collaboration to Co-Develop Industry-First AI Foundation Model for Longevity Science
May 26, 2026
Insilico Medicine and Ribo Enter Strategic Collaboration Agreement: Leveraging AI Platform and Automated Lab for End-to-End Empowerment of RNA Interference and Oligonucleotide Therapeutics Development
May 12, 2026
Insilico’s Rentosertib Inhalation Solution Receives IND Clearance for the World’s First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study
May 4, 2026
Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE
May 4, 2026
1
2
3
Next Page
→